<?xml version = '1.0' encoding = 'UTF-8'?>
<?xml-stylesheet href="/rss/styledrssBMC.css" type="text/css"?>
<rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns="http://purl.org/rss/1.0/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:extra="http://www.biomedcentral.com/xml/schemas/extra/" xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/" xmlns:cc="http://web.resource.org/cc/">
	<channel rdf:about="http://www.biomedcentral.com/rss">
		<extra:info rdf:parseType="Literal">
			<html:div xmlns:html="http://www.w3.org/1999/xhtml" style="font:14px Verdana, Geneva, Arial, Helvetica, sans-serif">
				<html:span style="font-weight:bold">This is an RSS newsfeed from BioMed Central</html:span>
				<html:br/>
				<html:span style="font-size: 12px;">It is intended to be used with an RSS reader. For more information about RSS newsfeeds from BioMed Central, visit <html:br/><html:a href="http://www.biomedcentral.com/info/about/rss/" style="color:#3333CC; font-size:12px;">http://www.biomedcentral.com/info/about/rss/</html:a><html:br/>
				</html:span>
			</html:div>
		</extra:info>
		<title>BMC Psychiatry - Latest articles</title>
		<link>http://www.biomedcentral.com/bmcpsychiatry/</link>
		<description>The latest articles from BMC Psychiatry (ISSN 1471-244X) published by 
				
				BioMed Central
		</description>
        <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        <items>
            <rdf:Seq>
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1471-244X/8/73"/>			    
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1471-244X/8/72"/>			    
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1471-244X/8/71"/>			    
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1471-244X/8/70"/>			    
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1471-244X/8/69"/>			    
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1471-244X/8/68"/>			    
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1471-244X/8/67"/>			    
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1471-244X/8/66"/>			    
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1471-244X/8/65"/>			    
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1471-244X/8/64"/>			    
            
            </rdf:Seq>
        </items>
    </channel>  
    
		<item rdf:about="http://www.biomedcentral.com/1471-244X/8/73">
            
            <title>The co-administration of quetiapine or placebo to cognitive-behavior therapy in treatment refractory depression; a preliminary trial</title>
			<description>Background:
Patients with major depression refractory to repeated pharmacological trials (TRD) may remain symptomatic for many years after their index episode. Augmentation strategies (with lithium or an atypical antipsychotic) or combining an antidepressant with short-term psychotherapy have been used with relative success in these patients. The aim of this study was to assess the effectiveness of the concomitant administration of quetiapine, an atypical antipsychotic, or placebo, to cognitive-behavior therapy (CBT) in TRD.  Methods. Thirty-one patients who met entrance criteria for unipolar major depression (TRD stage II or greater) underwent 3 weeks of lithium augmentation after which non-responders (N = 22) were randomized to receive either quetiapine or placebo as an adjunct to their 12 weekly CBT sessions  (quetiapine/CBT or placebo/CBT groups). Primary efficacy measures were the Hamilton and the Montgomery-Asberg rating scales for depression. Results. Overall, there was a significant reduction in both primary efficacy measure scores at LOCF for the 11 patients in the quetiapine/CBT group but not in the placebo/CBT treated patients. Patients in the quetiapine/CBT group, compared to those receiving placebo/CBT, showed a significantly greater degree of improvement on one primary and one secondary efficacy measure, were more likely to complete the trial and, completed a greater number of CBT sessions. Conclusion. Although preliminary, our results suggest that the adjunctive administration of quetiapine to CBT may prove useful in the treatment of stage II TRD. Trial Registration. Current Controlled Trials ISRCTN12638696.</description>
			<link>http://www.biomedcentral.com/1471-244X/8/73</link>
			
			 	<dc:creator>Yves Chaput, Annick Magnan and Alain Gendron</dc:creator>
			
			<dc:source>BMC Psychiatry 2008, 8:73</dc:source>
			<dc:date>2008-08-28</dc:date>
			<dc:identifier>doi:10.1186/1471-244X-8-73</dc:identifier>
			
			
							
					<prism:publicationName>BMC Psychiatry</prism:publicationName>
					
			
							
					<prism:issn>1471-244X</prism:issn>
					
			
							
					<prism:volume>8</prism:volume>
					
			
							
					<prism:startingPage>73</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-08-28</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.biomedcentral.com/1471-244X/8/72">
            
            <title>Costs of treating patients with schizophrenia
who have illness-related crisis events
</title>
			<description>Background:
Relatively little is known about the relationship between psychosocial crises and treatment costs for persons with schizophrenia. This naturalistic prospective study assessed the association of recent crises with mental health treatment costs among persons receiving treatment for schizophrenia.
Methods:
Data were drawn from a large multi-site, non-interventional study of schizophrenia patients in the United States, conducted between 1997 and 2003. Participants were treated at mental health treatment systems, including the Department of Veterans Affairs (VA) hospitals, community mental health centers, community and state hospitals, and university health care service systems. Total costs over a 1-year period for mental health services and component costs (psychiatric hospitalizations, antipsychotic medications, other psychotropic medications, day treatment, emergency psychiatric services, psychosocial/rehabilitation group therapy, individual therapy, medication management, and case management) were calculated for 1557 patients with complete medical information. Direct mental health treatment costs for patients who had experienced 1 or more of 5 recent crisis events were compared to propensity-matched samples of persons who had not experienced a crisis event. The 5 non-mutually exclusive crisis event subgroups were: suicide attempt in the past 4 weeks (n=18), psychiatric hospitalization in the past 6 months (n=240), arrest in the past 6 months (n=56), violent behaviors in the past 4 weeks (n=62), and diagnosis of a co-occurring substance use disorder (n=413).
Results:
Across all 5 categories of crisis events, patients who had a recent crisis had higher average annual mental health treatment costs than patients in propensity-score matched comparison samples. Average annual mental health treatment costs were significantly higher for persons who attempted suicide ($46,024), followed by persons with psychiatric hospitalization in the past 6 months ($37,329), persons with prior arrests ($31,081), and persons with violent behaviors  ($18,778). Total cost was not significantly higher for those with co-occurring substance use disorder ($19,034). 
Conclusions:
Recent crises, particularly suicide attempts, psychiatric hospitalizations, and criminal arrests, are predictive of higher mental health treatment costs in schizophrenia patients.</description>
			<link>http://www.biomedcentral.com/1471-244X/8/72</link>
			
			 	<dc:creator>Baojin Zhu, Haya Ascher-Svanum, Douglas E Faries, Xiaomei Peng, David Salkever and Eric P Slade</dc:creator>
			
			<dc:source>BMC Psychiatry 2008, 8:72</dc:source>
			<dc:date>2008-08-26</dc:date>
			<dc:identifier>doi:10.1186/1471-244X-8-72</dc:identifier>
			
			
							
					<prism:publicationName>BMC Psychiatry</prism:publicationName>
					
			
							
					<prism:issn>1471-244X</prism:issn>
					
			
							
					<prism:volume>8</prism:volume>
					
			
							
					<prism:startingPage>72</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-08-26</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.biomedcentral.com/1471-244X/8/71">
            
            <title>Acute maternal stress in pregnancy and schizophrenia in offspring: a cohort prospective study.</title>
			<description>	Schizophrenia has been linked with intrauterine exposure to maternal stress due to bereavement, famine and major disasters.  Recent evidence suggests that human vulnerability may be greatest in the first trimester of gestation and rodent experiments suggest sex specificity.  We aimed to describe the consequence of an acute maternal stress, through a follow-up of offspring whose mothers were pregnant during the Arab-Israeli war of 1967.  A priori, we focused on gestational month and offspring's sex.  Method:  In a pilot study linking birth records to Israel's Psychiatric Registry, we analyzed data from a cohort of 88,829 born in Jerusalem in 1964-76.  Proportional hazards models were used to estimate the relative risk (RR) of schizophrenia, according to month of birth, gender and other variables, while controlling for father's age and other potential confounders.  Other causes of hospitalized psychiatric morbidity (grouped together) were analyzed for comparison.  Results:  There was a raised incidence of schizophrenia for those who were in the second month of fetal life in June 1967 (RR =2.3, 1.1-4.7), seen more in females (4.3, 1.7-10.7) than in males (1.2, 0.4-3.8).  Results were not explained by secular or seasonal variations, altered birth weight or gestational age.  For other conditions, RRs were increased in offspring who had been in the third month of fetal life in June 1967 (2.5, 1.2-5.2), also seen more in females (3.6, 1.3-9.7) than males (1.8, 0.6-5.2).   Conclusions: These findings add to a growing literature, in experimental animals and humans, attributing long term consequences for offspring of maternal gestational stress.  They suggest both a sex-specificity and a relatively short gestational time-window for gestational effects on vulnerability to schizophrenia.</description>
			<link>http://www.biomedcentral.com/1471-244X/8/71</link>
			
			 	<dc:creator>D Malaspina, C Corcoran, K R Kleinhaus, M C Perrin, S Fennig, D Nahon, Y Friedlander and S Harlap</dc:creator>
			
			<dc:source>BMC Psychiatry 2008, 8:71</dc:source>
			<dc:date>2008-08-21</dc:date>
			<dc:identifier>doi:10.1186/1471-244X-8-71</dc:identifier>
			
			
							
					<prism:publicationName>BMC Psychiatry</prism:publicationName>
					
			
							
					<prism:issn>1471-244X</prism:issn>
					
			
							
					<prism:volume>8</prism:volume>
					
			
							
					<prism:startingPage>71</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-08-21</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.biomedcentral.com/1471-244X/8/70">
            
            <title>A systematic review of mental disorder, suicide, and deliberate self harm in lesbian, gay and bisexual people</title>
			<description>Background:
Lesbian, gay and bisexual (LGB) people may be at higher risk of mental disorders than heterosexual people.MethodWe conducted a systematic review and meta-analysis of the prevalence of mental disorder, substance misuse, suicide, suicidal ideation and deliberate self harm in LGB people. We searched Medline, Embase, PsycInfo, Cinahl, the Cochrane Library Database, the Web of Knowledge, the Applied Social Sciences Index and Abstracts, the International Bibliography of the Social Sciences, Sociological Abstracts, the Campbell Collaboration and grey literature databases for articles published January 1966 to April 2005.  We also used Google and Google Scholar and contacted authors where necessary.  We searched all terms related to homosexual, lesbian and bisexual people and all terms related to mental disorders, suicide, and deliberate self harm.   We included papers on population based studies which contained concurrent heterosexual comparison groups and valid definition of sexual orientation and mental health outcomes
Results:
Of 13706 papers identified, 476 were initially selected and 28 (25 studies) met inclusion criteria.  Only one study met all our four quality criteria and seven met three of these criteria.  Data was extracted on 214,344 heterosexual and 11,971 non heterosexual people.  Meta-analyses revealed a two fold excess in suicide attempts in lesbian, gay and bisexual people [pooled risk ratio for lifetime risk 2.47 (CI 1.87, 3.28)].  The risk for depression and anxiety disorders (over a period of 12 months or a lifetime) on meta-analyses were at least 1.5 times higher in lesbian, gay and bisexual people (RR range 1.54-2.58) and alcohol and other substance dependence over 12 months was also 1.5 times higher (RR range 1.51-4.00).  Results were similar in both sexes but meta analyses revealed that lesbian and bisexual women were particularly at risk of substance dependence (alcohol 12 months: RR 4.00, CI 2.85, 5.61; drug dependence: RR 3.50, CI 1.87, 6.53; any substance use disorder RR 3.42, CI 1.97-5.92), while lifetime prevalence of suicide attempt was especially high in gay and bisexual men (RR 4.28, CI 2.32, 7.88).
Conclusions:
LGB people are at higher risk of mental disorder, suicidal ideation, substance misuse, and deliberate self harm than heterosexual people.   </description>
			<link>http://www.biomedcentral.com/1471-244X/8/70</link>
			
			 	<dc:creator>Michael King, Joanna Semlyen, Sharon See Tai, Helen Killaspy, David Osborn, Dmitri Popelyuk and Irwin Nazareth</dc:creator>
			
			<dc:source>BMC Psychiatry 2008, 8:70</dc:source>
			<dc:date>2008-08-18</dc:date>
			<dc:identifier>doi:10.1186/1471-244X-8-70</dc:identifier>
			
			
							
					<prism:publicationName>BMC Psychiatry</prism:publicationName>
					
			
							
					<prism:issn>1471-244X</prism:issn>
					
			
							
					<prism:volume>8</prism:volume>
					
			
							
					<prism:startingPage>70</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-08-18</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.biomedcentral.com/1471-244X/8/69">
            
            <title>Randomised trials relevant to mental health conducted in low and middle-income countries: a survey</title>
			<description>Background:
A substantial proportion of the psychiatric burden of disease falls on the world's poorest nations, yet relatively little is known about randomised trials conducted in these countries. Our aim was to identify and describe a representative sample of mental health trials from low and middle-income countries.
Methods:
6107 electronic records, most with full text copies, were available following extensive searches for randomised or potentially randomised trials from low and middle-income countries published in 1991, 1995 and 2000. These records were searched to identify studies relevant to mental health. Data on study characteristics were extracted from the full text copies.
Results:
Trials relevant to mental health were reported in only 3% of the records. 176 records reporting 177 trials were identified: 25 were published in 1991, 45 in 1995, and 106 in 2000. Participants from China were represented in 46% of trials described. 68% of trials had &lt;100 participants. The method of sequence generation was described in less than 20% of reports and adequate concealment of allocation was described in only 12% of reports. Participants were most frequently adults with unipolar depression (36/177) or schizophrenia (36/177). 80% of studies evaluated pharmacological interventions, a third of which were not listed by WHO as essential drugs. 41% of reports were indexed on PubMed; this proportion decreased from 68% in 1991 to 32% in 2000.
Conclusion:
In terms of overall health burden, trial research activity from low and middle-income countries in mental health appears to be low, and in no area adequately reflects need.</description>
			<link>http://www.biomedcentral.com/1471-244X/8/69</link>
			
			 	<dc:creator>Rebecca J Syed Sheriff, Clive E Adams, Prathap Tharyan, Mahesh Jayaram, Lelia Duley and the PRACTIHC Mental Health Group</dc:creator>
			
			<dc:source>BMC Psychiatry 2008, 8:69</dc:source>
			<dc:date>2008-08-14</dc:date>
			<dc:identifier>doi:10.1186/1471-244X-8-69</dc:identifier>
			
			
							
					<prism:publicationName>BMC Psychiatry</prism:publicationName>
					
			
							
					<prism:issn>1471-244X</prism:issn>
					
			
							
					<prism:volume>8</prism:volume>
					
			
							
					<prism:startingPage>69</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-08-14</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.biomedcentral.com/1471-244X/8/68">
            
            <title>The importance of the concepts of disaster, catastrophe, violence, trauma and barbarism in defining posttraumatic stress disorder in clinical practice</title>
			<description>Background:
Several terms in the scientific literature about posttraumatic stress disorder are used with different meanings in studies conducted by different authors. Words such as trauma, violence, catastrophe, disaster and barbarism are often used vaguely or confusingly, and their meanings change in different articles. The lack of conceptual references for these expressions complicates the organization of literature. Furthermore, the absence of clear concepts may be an obstacle to clinical treatment because the use of these words by the patients does not necessarily point to a diagnosis of posttraumatic stress disorder.DiscussionA critical review of scientific literature showed that stress can be divided in stages to facilitate specific terminological adjustments to the event itself, to the subject-event interaction and to psychological responses. Moreover, it demonstrated that the varying concept of trauma expands into fundamental psychotherapeutic definitions and that the meanings of violence associated with barbarism are an obstacle to resilience. Therefore, this study updates the etymological origins and applications of these words, connects them to the expansions of meanings that can be operated in the clinical care of patients with posttraumatic stress disorder, and analyzes them critically according to the criterion A of DSM-IV and ICD-10.SummaryThe terminology in the literature about posttraumatic stress disorder includes a plethora of terms whose meanings are not fully understood, and that, therefore, limit this terminology. The analysis of these terms suggested that the transformation of the concept of trauma led to a broader understanding of this phenomenon in its psychic dimensions, that a barbarian type of violence constitutes an obstacle to resilience, and that the criterion A of the DSM-IV and ICD-10 shows imprecision and conceptual fragilities. </description>
			<link>http://www.biomedcentral.com/1471-244X/8/68</link>
			
			 	<dc:creator>Luciana L Braga, Jose P Fiks, Jair J Mari and Marcelo F Mello</dc:creator>
			
			<dc:source>BMC Psychiatry 2008, 8:68</dc:source>
			<dc:date>2008-08-12</dc:date>
			<dc:identifier>doi:10.1186/1471-244X-8-68</dc:identifier>
			
			
							
					<prism:publicationName>BMC Psychiatry</prism:publicationName>
					
			
							
					<prism:issn>1471-244X</prism:issn>
					
			
							
					<prism:volume>8</prism:volume>
					
			
							
					<prism:startingPage>68</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-08-12</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.biomedcentral.com/1471-244X/8/67">
            
            <title>The incidence and prevalence of diabetes in patients with serious mental illness in North West Wales: Two cohorts, 1875&#8211;1924 &amp; 1994&#8211;2006 compared</title>
			<description>Background:
Against a background of interest in rates of diabetes in schizophrenia and related psychoses and claims that data from historical periods demonstrate a link that antedates modern antipsychotics, we sought to establish the rate of diabetes in first onset psychosis and subsequent prevalence in historical and contemporary cohorts.
Methods:
Analysis of two epidemiologically complete databases of individuals admitted for mental illness. 3170 individuals admitted to the North Wales Asylum between 1875&#8211;1924 and tracked over 18,486 patient years and 394 North West Wales first admissions for schizophrenia and related psychoses between 1994 and 2006 and tracked after treatment.
Results:
The prevalence of Type 2 diabetes among patients with psychoses at time of first admission in both historical and contemporary samples was 0%. The incidence of diabetes remained 0% in the historical sample throughout 15 years of follow-up but rose in the contemporary sample after 3, 5 and 6 years of treatment with an incidence rate double the expected population rate so that the 15 year prevalence is likely to be over 8%.
Conclusion:
No association was found between diabetes and serious mental illness, but there may be an association between diabetes and treatment.</description>
			<link>http://www.biomedcentral.com/1471-244X/8/67</link>
			
			 	<dc:creator>Joanna Le Noury, Afshan Khan, Margaret Harris, Winnie Wong, Dawn Williams, Tony Roberts, Richard Tranter and David Healy</dc:creator>
			
			<dc:source>BMC Psychiatry 2008, 8:67</dc:source>
			<dc:date>2008-08-07</dc:date>
			<dc:identifier>doi:10.1186/1471-244X-8-67</dc:identifier>
			
			
							
					<prism:publicationName>BMC Psychiatry</prism:publicationName>
					
			
							
					<prism:issn>1471-244X</prism:issn>
					
			
							
					<prism:volume>8</prism:volume>
					
			
							
					<prism:startingPage>67</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-08-07</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.biomedcentral.com/1471-244X/8/66">
            
            <title>Reduced neural synchronization of gamma-band MEG oscillations in first-degree relatives of children with autism</title>
			<description>Background:
Gamma-band oscillations recorded from human electrophysiological recordings, which may be associated with perceptual binding and neuronal connectivity, have been shown to be altered in people with autism. Transient auditory gamma-band responses, however, have not yet been investigated in autism or in the first-degree relatives of persons with the autism.
Methods:
We measured transient evoked and induced magnetic gamma-band power and inter-trial phase-locking consistency in the magnetoencephalographic recordings of 16 parents of children with autism, 11 adults with autism and 16 control participants. Source space projection was used to separate left and right hemisphere transient gamma-band measures of power and phase-locking.
Results:
Induced gamma-power at 40 Hz was significantly higher in the parent and autism groups than in controls, while evoked gamma-band power was reduced compared to controls. The phase-locking factor, a measure of phase consistency of neuronal responses with external stimuli, was significantly lower in the subjects with autism and the autism parent group, potentially explaining the difference between the evoked and induced power results.
Conclusion:
These findings, especially in first degree relatives, suggest that gamma-band phase consistency and changes in induced versus induced power may be potentially useful endophenotypes for autism, particularly given emerging molecular mechanisms concerning the generation of gamma-band signals.</description>
			<link>http://www.biomedcentral.com/1471-244X/8/66</link>
			
			 	<dc:creator>Donald C Rojas, Keeran Maharajh, Peter Teale and Sally J Rogers</dc:creator>
			
			<dc:source>BMC Psychiatry 2008, 8:66</dc:source>
			<dc:date>2008-08-01</dc:date>
			<dc:identifier>doi:10.1186/1471-244X-8-66</dc:identifier>
			
			
							
					<prism:publicationName>BMC Psychiatry</prism:publicationName>
					
			
							
					<prism:issn>1471-244X</prism:issn>
					
			
							
					<prism:volume>8</prism:volume>
					
			
							
					<prism:startingPage>66</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-08-01</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.biomedcentral.com/1471-244X/8/65">
            
            <title>Identifying patterns in treatment response profiles in acute bipolar mania: a cluster analysis approach</title>
			<description>Background:
Patients with acute mania respond differentially to treatment and, in many cases, fail to obtain or sustain symptom remission. The objective of this exploratory analysis was to characterize response in bipolar disorder by identifying groups of patients with similar manic symptom response profiles.
Methods:
Patients (n = 222) were selected from a randomized, double-blind study of treatment with olanzapine or divalproex in bipolar I disorder, manic or mixed episode, with or without psychotic features. Hierarchical clustering based on Ward's distance was used to identify groups of patients based on Young-Mania Rating Scale (YMRS) total scores at each of 5 assessments over 7 weeks. Logistic regression was used to identify baseline predictors for clusters of interest.
Results:
Four distinct clusters of patients were identified: Cluster 1 (n = 64): patients did not maintain a response (YMRS total scores &#8804; 12); Cluster 2 (n = 92): patients responded rapidly (within less than a week) and response was maintained; Cluster 3 (n = 36): patients responded rapidly but relapsed soon afterwards (YMRS &#8805; 15); Cluster 4 (n = 30): patients responded slowly (&#8805; 2 weeks) and response was maintained. Predictive models using baseline variables found YMRS Item 10 (Appearance), and psychosis to be significant predictors for Clusters 1 and 4 vs. Clusters 2 and 3, but none of the baseline characteristics allowed discriminating between Clusters 1 vs. 4. Experiencing a mixed episode at baseline predicted membership in Clusters 2 and 3 vs. Clusters 1 and 4. Treatment with divalproex, larger number of previous manic episodes, lack of disruptive-aggressive behavior, and more prominent depressive symptoms at baseline were predictors for Cluster 3 vs. 2.
Conclusion:
Distinct treatment response profiles can be predicted by clinical features at baseline. The presence of these features as potential risk factors for relapse in patients who have responded to treatment should be considered prior to discharge.Trial registrationThe clinical trial cited in this report has not been registered because it was conducted and completed prior to the inception of clinical trial registries.</description>
			<link>http://www.biomedcentral.com/1471-244X/8/65</link>
			
			 	<dc:creator>Ilya A Lipkovich, John P Houston and Jonna Ahl</dc:creator>
			
			<dc:source>BMC Psychiatry 2008, 8:65</dc:source>
			<dc:date>2008-07-29</dc:date>
			<dc:identifier>doi:10.1186/1471-244X-8-65</dc:identifier>
			
			
							
					<prism:publicationName>BMC Psychiatry</prism:publicationName>
					
			
							
					<prism:issn>1471-244X</prism:issn>
					
			
							
					<prism:volume>8</prism:volume>
					
			
							
					<prism:startingPage>65</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-07-29</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.biomedcentral.com/1471-244X/8/64">
            
            <title>An approach to measure compliance to clinical guidelines in psychiatric care</title>
			<description>Background:
The aim of this study was to measure six months compliance to Swedish clinical guidelines in psychiatric care after an active supported implementation process, using structured measures derived from the guidelines.
Methods:
In this observational study four psychiatric clinics each participated in active implementation of the clinical guidelines for the assessment and treatment of depression and guidelines for assessment and treatment of patients with suicidal behaviours developed by The Stockholm Medical Advisory Board for Psychiatry. The implementation programme included seminars, local implementation teams, regular feedback and academic visits. Additionally two clinics only received the guidelines and served as controls. Compliance to guidelines was measured using indicators, which operationalised requirements of preferred clinical practice. 725 patient records were included, 365 before the implementation and 360 six months after.
Results:
Analyses of indicators registered showed that the actively implementing clinics significantly improved their compliance to the guidelines. The total score differed significantly between implementation clinics and control clinics for management of depression (mean scores 9.5 (1.3) versus 5.0 (1.5), p &lt; 0.001) as well as for the management of suicide (mean scores 8.1 (2.3) versus 4.5 (1.9), p &lt; 0.001). No changes were found in the control clinics and only one of the OR was significant.
Conclusion:
Compliance to clinical guidelines measured by process indicators of required clinical practice was enhanced by an active implementation.</description>
			<link>http://www.biomedcentral.com/1471-244X/8/64</link>
			
			 	<dc:creator>Tord Forsner, Anna &#197;berg Wistedt, Mats Brommels and Yvonne Forsell</dc:creator>
			
			<dc:source>BMC Psychiatry 2008, 8:64</dc:source>
			<dc:date>2008-07-25</dc:date>
			<dc:identifier>doi:10.1186/1471-244X-8-64</dc:identifier>
			
			
							
					<prism:publicationName>BMC Psychiatry</prism:publicationName>
					
			
							
					<prism:issn>1471-244X</prism:issn>
					
			
							
					<prism:volume>8</prism:volume>
					
			
							
					<prism:startingPage>64</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-07-25</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
		
    <cc:License rdf:about="http://creativecommons.org/licenses/by/2.0/">
         <cc:permits rdf:resource="http://creativecommons.org/ns#Reproduction"/>
         <cc:permits rdf:resource="http://creativecommons.org/ns#Distribution"/>
         <cc:permits rdf:resource="http://creativecommons.org/ns#DerivativeWorks"/>
	</cc:License>
</rdf:RDF>
